Treatment of erythematotelangiectatic rosacea, facial erythema, and facial telangiectasia with a 577-nm pro-yellow laser: a case series

Basit Öğe Kaydı
dc.authoridCenk, Hülya/0000-0003-4871-6342;
dc.authorwosidCenk, Hülya/A-1293-2016
dc.authorwosidSarac, Gulbahar/ABF-3119-2020
dc.contributor.authorKapicioglu, Yelda
dc.contributor.authorSarac, Gulbahar
dc.contributor.authorCenk, Hulya
dc.date.accessioned2024-08-04T20:45:22Z
dc.date.available2024-08-04T20:45:22Z
dc.date.issued2019
dc.departmentİnönü Üniversitesien_US
dc.description.abstractVarious lasers have been used for the treatment of erythematotelangiectatic rosacea (ETR), facial erythema (FE), and facial telangiectasias (FT). The assessment of the treatments of all of these conditions with a 577-nm pro-yellow laser has not been reported yet. The aim of this work was to assess the efficacy and safety of the 577-nm pro-yellow laser in ETR, FE, and FT. Forty patients suffering from ETR, FE, and FT (25 female and 15 male) were enrolled in this study. All of the patients were treated with 577-nm pro-yellow laser (QuadroStarPRO YELLOW (R) Asclepion Laser Technologies, Germany) at 4-week intervals, for one to four sessions. The assessment of the treatment was made based on the digital photographs and the percentage of fading of the erythema and telangiectasias in the lesions. Significant clinical improvement (80-100%) was observed in the first or second sessions of the treatment in FE and ETR patients and in second and fourth sessions of the treatment in FT patients. The treatment was very well tolerated. No side effect was observed except for a few patients who had mild to moderate erythema fading away in 12-24h. This case series has shown that the pro-yellow laser is a very effective, safe, and well-tolerated treatment for ETR, FE, and FT.en_US
dc.identifier.doi10.1007/s10103-018-2606-6
dc.identifier.endpage98en_US
dc.identifier.issn0268-8921
dc.identifier.issn1435-604X
dc.identifier.issue1en_US
dc.identifier.pmid30097757en_US
dc.identifier.scopus2-s2.0-85051289515en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage93en_US
dc.identifier.urihttps://doi.org/10.1007/s10103-018-2606-6
dc.identifier.urihttps://hdl.handle.net/11616/98423
dc.identifier.volume34en_US
dc.identifier.wosWOS:000456450200012en_US
dc.identifier.wosqualityQ2en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherSpringer London Ltden_US
dc.relation.ispartofLasers in Medical Scienceen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectTreatment of rosaceaen_US
dc.subjectLaser treatmenten_US
dc.subjectPro-yellow laseren_US
dc.subjectFacial erythemaen_US
dc.titleTreatment of erythematotelangiectatic rosacea, facial erythema, and facial telangiectasia with a 577-nm pro-yellow laser: a case seriesen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu